Rusia ofreció a diversas entidades sanitarias, agencias y especialistas de Latinoamérica un medicamento llamado "Avifavir" para combatir la COVID-19 en un período de entre cuatro y diez días. El fármaco ha sido probado en más de 30 mil pacientes con resultados favorables. Fuente: [TV Perú]
:quality(75)/cdn.jwplayer.com/v2/media/krBFTHLV/poster.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/07-12-2020/t_57c13e200b1646f2b68e8cc244f0aa4b_name_C07_RUSIA.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/BSCwKrLR/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/N1W5L0Zs/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QZDKTCLGKFBLTHDE2SYRDONVKA.png)
:quality(75)/cdn.jwplayer.com/v2/media/N1W5L0Zs/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ssYh1XFB/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/rb34LltV/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/tsbDQ6Q6/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ZJRMYQTLGVFTTCQZDWD6JUNJ34.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FACEUXZLE5DNHFQEAYVP66PHSI.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/R6SKFHJNSNHUZAUHKVEQRZDCKI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/D3QIGZJICZHKTKAHS4C2NRRIXI.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/BSCwKrLR/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/TspxfC6e/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/plwq4ENJ/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/57u0c2nL/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/krBFTHLV/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QZDKTCLGKFBLTHDE2SYRDONVKA.png)
:quality(75)/cdn.jwplayer.com/v2/media/dYzvyk19/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xdmtbo3R/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/juAVPNx9/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yksVgSj8/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/wXUo9jVU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yOEdb2ys/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JDVYxTbd/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/LIy1dI2W/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xv8iJGpA/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)